ACE inhibitors and angiotensin II receptor antagonists in Crohn's disease management

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 5, 2008, Pages 645-651

  Hume, Georgia E ^a,b,c   Radford Smith, Graham L ^a,b,c  

^a Royal Brisbane and Womens Hospital Research Foundation   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Angiotensin II receotor antagonist; Angiotensin converting enzyme inhibitor; Crohn's disease; Renin angiotensin aldosterone; TGF

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLUCOCORTICOID; LISINOPRIL; LOSARTAN; QUINAPRIL; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA;

ANTIINFLAMMATORY ACTIVITY; CHRONIC INFLAMMATION; COLITIS; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EVIDENCE BASED MEDICINE; FIBROSIS; HUMAN; HYPERTENSION; LOW DRUG DOSE; MICROVASCULAR ISCHEMIA; MONOTHERAPY; NEPHRITIS; NONHUMAN; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SPLANCHNIC BLOOD FLOW; TREATMENT INDICATION; VASOCONSTRICTION;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CROHN DISEASE; DISEASE MODELS, ANIMAL; GASTROINTESTINAL TRACT; HUMANS; MICE; RENIN-ANGIOTENSIN SYSTEM;

EID: 55349127481     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.5.645     Document Type: Review

References (64)

1. Gavras H, Brunner HR, Turini GA et al. Antihypertensive effect of the oral angiotensin-converting enzyme inhibitor SQ 14225 in man. N. Engl. J. Med. 298(18), 991-995 (1978).
2. Goldblatt H. The renal origin of hypertension. Physiol. Rev. 27 (1), 120-165 (1947).
3. Skeggs LT, Kahn JR, Shumway NP. The preparation and function of the hypertension-conver ting enzyme. J. Exp. Med. 103(3), 295-299 (1956).
4. Ng KKF, Vane JR. Conversion of angiotensin I to angiotensin II. Nature 216(5117), 762-766 (1967).
5. Peach, MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol. Rev. 57(2), 313-370 (1977).
6. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 316(23), 1429-1435 (1987).
7. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325(5), 293-302 (1991).
8. Pfeffer MA, Braunwald E, Moyé LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N. Engl. J. Med. 327(10), 669-677 (1992).
9. Imbs JL, Schmidt M, Giesen E-M, Schwartz J. Effect of captopril on intrarenal blood flow. Am. J. Med. 76(5B), 53-57 (1984).
10. Ichikawa I, Harris RC. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int. 40(4), 583-596 (1991).
11. Studdy P, Bird R, Geraint James D, Sherlock S. Serum angiotensin-converting enzyme (SACE) in sarcoidosis and other granulomatous disorders. Lancet 2(8104-8105), 1331-1334 (1978).
12. Matsuda T, Suzuki J, Furuya K, Masutani M. Kawakami Y. Serum angiotensin I-converting enzyme is reduced in Crohn's disease and ulcerative colitis irrespective of genoptype. Am. J. Gastroenterol. 96(9), 2705-2710 (2001).
13. Takeuchi N, Fukushima T, Sugita A, Tsuchiya S. Angiotensin-converting enzyme (ACE) in Crohn's disease. Jap. J. Gastroenterol. 89(3), 596-600 (1992).
14. Sommer H, Schweisfurth H, Schulz M. Serum angiotensin-I-converting enzyme and carboxypeptidase N in Crohn's disease and ulcerative colitis. Enzyme 35(4), 181-188 (1986).
15. Silverstein E, Fiest SM, Simon MR, Weinstock JV, Friedland J. Angiotensin-converting enzyme in Crohn's disease and ulcerative colitis. Am. J. Clin. Pathol. 75(2), 175-178 (1981).
16. Jaszewski R, Tolia V, Ehrinpresis MN et al. Increased colonic mucosal angiotensin I and II concentrations in Crohn's colitis. Gastroenterology 98(6), 1543-1548 (1990).
17. Wengrower D, Zannineli G, Pappa O et al. Prevention of fibrosis in experimental colitis by captopril: the role of TGF-β1. Inflamm. Bowel Dis. 10(5), 536-545 (2004).
18. Jahovic N, Ercan F, Gedik N, Yuksel M, Sener G, Alican I. The effect of angiotensin-converting enzyme inhibitors on experimental colitis in rats. Regul. Pept. 130(1-2), 67-74 (2005),
19. Spencer A, Yang H, Haxhija E, Wildhaber BE, Greenson JK, Teitelbaum DH. Reduced severity of a mouse colitis model with angiotensin-converting enzyme inhibition. Dig Dis. Sci. 52(4), 1060-1070 (2007).
20. Inokuchi Y, Morohashi T, Kawana I, Nagashima Y, Kihara M, Umemura S. Amelioration of 2,4,6-trinitrobenzene sulphonic acid induced colitis in angiotensinogen gene knockout mice. Gut 54(3), 349-356 (2005).
21. Burnier M. Angiotensin II receptor blockers. Circulation 103(6), 904-912 (2001).
22. Unger TU, Stoppelhaar M. Rationale for double renin-angiotensin-aldosterone system blockade. Am. J. Cardiol. 100(Suppl.), 25J-31J (2007).
23. Ferrario CM, Chappell MC. Novel Angiotensin peptides. Cell. Mol. Life Sci. 61(21), 2720-2727 (2004).
24. Danilczyk U, Eriksson U, Oudit GY, Penninger JM. Physiological roles of angiotensin-converting enzyme 2. Cell. Mol. Life Sci. 61(21), 2714-2719 (2004).
25. Zani A, Eaton S, Lenn FF et al. Captopril reduces the severity of bowel damage in a neonatal rat model of necrotizing enterocolitis. J. Pediatr. Surg. 43(2), 308-314 (2008).
26. Thornton M, Solomon MJ. Crohn's disease: in defense of a microvascular aetiology. Int. J. Colorectal Dis. 17(5), 287-297 (2002).
27. Jones WG 2nd, Minei JP, Barber AE, Fahey TJ 3rd, Shires GT 3rd, Shires GT. Splanchnic vasoconstriction and bacterial translocation after thermal injury. Am. J. Physiol. 261 (4 Pt 2), Hl190-Hl196 (1991).
28. Laesser M, Oi Y, Ewert S, Fandriks L, Aneman A. The angiotensin II receptor blocker candesartan improves survival and mesenteric perfusion in an acute porcine endotoxin model. Acta Anaesthesiol. Scand. 48(2), 198-204 (2004).
29. Tadros T, Traber DL, Heggers JP, Herndon DN. Angiotensin II inhibitor DuP753 attenuates burn- and endotoxin-induced gut ischemia, lipid peroxidation, mucosal permeability, and bacterial translocation. Ann. Surg. 231(4), 566-576 (2000).
30. Shimada K, Yakazi Y. Binding sites of angiotensin II in human mononuclear cells. J. Biochem. 84(4), 1013-1015 (1978).
31. Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, Lorenzo O, Plaza J, Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immunce complex nephritis through nuclear factor-ΚB activation and monocyte chemoattractant protein-1 synthesis. J. Immunol. 161(1), 430-439 (1998).
32. Williams B, Baker AQ, Gallacher B, Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 25(5), 913-917 (1995).
33. Gräfe M, Auch-Schwelk W, Zakrzewicz A et al. Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ. Res. 81(5), 804-811 (1997).
34. Pastore L, Tessitore A, Martinotti S et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 100(15), 1646-1652 (1999).
35. Brasier AR, Li J. Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension 27(3 Pt 2), 465-475 (1996).
36. Kageyama R, Ohkubo H, Nakanishi S. Induction of rat liver angiotensinogen mRNA following acute inflammation. Biochem. Biophys. Res. Commun. 129(3), 826-832 (1985).
37. Kohara K, Brosnihan KB, Ferrario CM, Milsted A. Peripheral and central angiotensin II regulates expression of genes of the Renin-angiotensin system. Am. J. Physiol. 262(5 Pt 1), E651-E657 (1992).
38. Eggena P, Zhu JH, Clegg K, Barrett JD. Nuclear angiotensin receptors induce transcription of renin and angiotensinogen mRNA. Hypertemion 22(4), 496-501 (1993).
39. Krakoff LR. Measurement of plasma-renin substrate by radioimmunoassay of angiotensin I: concentration in syndromes associated with steroid excess. J. Clin. Endcrinol. Metab. 37(1), 110-117 (1973).
40. Moriyama T, Fujibayashi M, Fujiwara Y et al. Angiotensin II stimulates interkeukin-6 release from cultured mouse mesangial cells. J. Am. Soc. Nephrol. 6(1), 95-101 (1995).
41. Nakamura A, Johns EJ, Imaizumi A, Yanagawa Y, Kohsaka T. Effect of β(2)-adrenoceptor activation and angiotensin II on tumour necrosis factor and interleukin 6 gene transcription in the rat renal resident macrophage cells. Cytokine 11 (10), 759-765 (1999).
42. Ruiz-Ortega M, Ruperez M, Lorenzo O. et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int. Suppl. 82, 12-22 (2002).
43. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proinflammatory actions of angiotensins. Curr. Opin. Nephrol. Hypertens. 10(3), 321-329 (2001).
44. Bacher S, Schmitz ML. The NF-ΚB pathway as a potential target for autoimmune disease therapy. Curr. Pharm. Des. 10(23), 2827-2837 (2004).
45. Matsusaka T, Ichikawa I. Biological functions of angiotensin and its receptors. Annu. Rev. Physiol. 59, 395-412 (1997).
46. Wolf G, Haberstroh U, Neilson EG. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am. J. Pathol. 140(1), 95-107 (1992).
47. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J. Clin. lnvest. 93(6), 2431-2437 (1994).
48. Border WA, Noble NA. Interactions of transforming growth factor-β and angiotensin li in renal fibrosis. Hypertension 31(1 Pt 2), 181-188 (1998).
49. Shin GT, Kim SJ, Ma KI, Kim HS, Kim D. ACE inhibitors attenuate expression of renal transforming growth factor-β 1 in humans. Am. J. Kidney Dis. 36(5), 894-902 (2000).
50. Rupérez M, Ruiz-Ortega M, Esteban V et al. Angiotensin II increases connective tissue growth factor in the kidney. Am. J. Pathol. 163(5),1937-1947 (2003).
51. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J. Am. Soc. Nephrol. 17(11), 2985-2991 (2006).
52. Dubuquoy L, Dharancy S, Nutten S, Pettersson S, Auwerx J, Desreumaux P. Role of peroxisome proliferator-activated receptor γ and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 360(9343), 1410-1418 (2002).
53. Levens NR. Control of intestinal absorption by the renin-angiotensin system. Am. J. Physiol. 249(1 Pt 1), G3-G15 (1985).
54. Hirasawa K, Sato Y, Hosoda Y, Yamamoto. T, Hanai H. Immunohistochemical localisation of angiotensin II receptor and local renin-angiotensin system in human colonic mucosa. J. Histochem. Cyotchem. 50(2), 275-282 (2002).
55. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am. J. Physiol. 277(2), C183-C201 (1999).
56. Spak E, Casselbrant A, Olbers T, Lonroth H, Fandriks L. Angiotensin II-induced contractions in human jejunal wall musculature in vitro. Acta Physiol. 193(2), 181-190 (2008).
57. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96(3), 795-803 (1989).
58. Vetuschi A, Latella G, Sferra R, Caprilli R, Gaudio E. Increased prolifetation and apoptosis of colonic epkhelial cells in dextran sulfate sodium-induced colitis in rats. Dig. Dis. Sci. 47(7), 1447-1457 (2002).
59. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55(6), 749-753 (2006).
60. Lautenbach E, Berlin JA, Lichtenstein GR. Risk factors for early postoperative recurrence of Crohn's disease. Gastroenterology 115(2), 259-267 (1998).
61. Powell EE, Edwards-Smith CJ, Hay JL et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31 (4), 828-833 (2000).
62. Inoue I, Nakajima T, Williams CS et al. A nucleotide Substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J. Clin. Invest. 99(7), 1786-1797 (1997).
63. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-β1 gene: association with transforming growth factor-β1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 66(8), 1014-1020 (1998).
64. Hume GE, Fowler EV, Lincoln D et al. Angiotensinogen and transforming growth factor β1: novel genes in the pathogenesis of Crohn's disease. J. Med. Genet. 43(10), E51 (2006),